Comparison of the efficacy and safety of quinapril vs. captopril in treatment of moderate to severe hypertension.
The results of this multicenter double-blind comparative study in 172 patients with moderate to severe hypertension indicate that twice daily quinapril (20-80 mg/day) is significantly more effective than captopril (50-200 mg/day) at reducing blood pressure. Following a minimum of four weeks of treatment, the results in evaluable patients showed a significantly greater reduction of diastolic blood pressure (DBP) in the quinapril group than in the captopril group (18.6 vs 15.3 mm Hg, respectively, p less than 0.05). An intent-to-treat analysis using blood pressure data from all patients having values within an eight-to-sixteen-hour postdose treatment window showed quinapril to produce a significantly greater reduction in DBP than captopril (18.2 vs 14.8 mm Hg, respectively, p = less than 0.05). Throughout the course of the six-week study, quinapril consistently showed efficacy superior to captopril despite a faster captopril dose titration.
Schnaper
H W
HW
University of Alabama, Birmingham.
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D002216:Captopril / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D007546:Isoquinolines / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D000077583:Quinapril; D011897:Random Allocation; D044005:Tetrahydroisoquinolines
D000806:Angiotensin-Converting Enzyme Inhibitors; D007546:Isoquinolines; D044005:Tetrahydroisoquinolines; D002216:Captopril; D000077583:Quinapril